- Home
- TCRT vs TRIB Comparison
TCRT vs TRIB Comparison
Compare TCRT & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- TRIB
- Stock Information
- Founded
- TCRT 1998
- TRIB 1992
- Country
- TCRT United States
- TRIB Ireland
- Employees
- TCRT N/A
- TRIB N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TCRT Health Care
- TRIB Health Care
- Exchange
- TCRT Nasdaq
- TRIB Nasdaq
- Market Cap
- TCRT 5.5M
- TRIB 5.4M
- IPO Year
- TCRT N/A
- TRIB N/A
- Fundamental
- Price
- TCRT N/A
- TRIB $1.09
- Analyst Decision
- TCRT
- TRIB
- Analyst Count
- TCRT 0
- TRIB 0
- Target Price
- TCRT N/A
- TRIB N/A
- AVG Volume (30 Days)
- TCRT 47.7K
- TRIB 101.5K
- Earning Date
- TCRT 11-13-2025
- TRIB 11-14-2025
- Dividend Yield
- TCRT N/A
- TRIB N/A
- EPS Growth
- TCRT N/A
- TRIB N/A
- EPS
- TCRT N/A
- TRIB N/A
- Revenue
- TCRT $6,000.00
- TRIB $61,555,000.00
- Revenue This Year
- TCRT $5,680,500.00
- TRIB $13.51
- Revenue Next Year
- TCRT N/A
- TRIB $13.14
- P/E Ratio
- TCRT N/A
- TRIB N/A
- Revenue Growth
- TCRT N/A
- TRIB 8.31
- 52 Week Low
- TCRT $1.31
- TRIB $0.48
- 52 Week High
- TCRT $6.20
- TRIB $3.44
- Technical
- Relative Strength Index (RSI)
- TCRT 66.77
- TRIB 44.39
- Support Level
- TCRT $2.44
- TRIB $1.00
- Resistance Level
- TCRT $3.17
- TRIB $1.17
- Average True Range (ATR)
- TCRT 0.19
- TRIB 0.07
- MACD
- TCRT 0.06
- TRIB -0.00
- Stochastic Oscillator
- TCRT 81.81
- TRIB 30.48
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.